Gankyrin RNA Interference (RNAi) Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Human cells contain two critical types of genes: "oncogenes" that drive cell division and "tumor suppressor genes" that act as brakes. When suppressors are damaged by environment, stress, or genetics, cells proliferate uncontrollably, forming cancer. The Gankyrin RNAi Therapy at Tenjin Cancer Clinic aims to reshape this balance at the genetic level.
What is Gankyrin?
Gankyrin is a specific protein-coding gene frequently overexpressed in various malignancies. It acts as a "blocker," strongly inhibiting well-known tumor suppressors such as p53, p16, PTEN, and RB, rendering these guardians ineffective.
- p53 Gene: Known as the "Guardian of the Genome," responsible for inducing apoptosis in cancerous cells.
- p16 Gene: Prevents cancer by delaying abnormal cell proliferation.
How the Genetic Therapy Works
- RNA Suppression: Specific inhibitory RNA is administered via intravenous infusion to precisely target and neutralize the expression of the Gankyrin gene.
- Unleashing Suppressor Power: Once the interference from Gankyrin is removed, the previously suppressed p53 and p16 genes regain their activity.
- Inducing Apoptosis: The restored tumor suppressors trigger cell death mechanisms, causing cancer cells to self-destruct while inhibiting infiltration and metastasis.
Treatment Features and Cycle
- Precision Medicine: Unlike traditional surgery or high-side-effect chemotherapy, gene therapy focuses on "precision correction" with minimal damage to healthy cells.
- Treatment Cycle: Patients typically visit the clinic every 1–2 weeks for an infusion.
- Use with other therapies: Whether it is combined with TRAIL gene therapy is determined by a physician; the effect of such combinations has not been established.
Medical Institution: Tenjin Cancer Clinic, Fukuoka
This clinic offers self-pay cancer gene therapy and is located in Fukuoka's Chuo Ward. The team emphasizes coordination with the patient's attending physician; the effectiveness and safety of cancer gene therapy have not been established, so please discuss suitability with your attending physician first.
[Medical Supporter Compliance Statement] Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.